1001138302 Ontario Inc. has been in a court-appointed receivership since April 30, 2024, brought under section 243 of the Bankruptcy and Insolvency Act and provincial Judicature Act authority in the Ontario Superior Court of Justice, under court file CV-24-00719237-00CL. The proceeding is recorded on the court's Commercial List and in its bankruptcy and insolvency jurisdiction in Ontario. The proceeding remains active. The record to date contains a single filing: a report by a court officer bearing the same date as the commencement of the receivership. No further steps have been entered on the record.
The claims bar date has passed — claims were due by
Per the Notice to Claimants dated 26 June 2024.
The officer filed report no. Fourth Interim Report. The Receiver has collected the last remaining sales tax refunds owed to ResidualCo, completed an interim distribution to creditors, and is now working through final tax filings before seeking a final distribution and discharge. Court file CV-24-00719237-00CL.
Source: Fourth Interim Report of the Receiver- Section 246(2) of the BIA
Receiver's Certificate, re: Closing of sale transaction to Taro Pharmaceuticals Inc. — Court officer certificate
Proof of Claim Form for Claims against Antibe Therapeutics Inc. — Proof of claim (blank form)
A claims procedure was approved, setting a claims bar date of 2024-08-30.
Source: Claims Procedure Order
A claims procedure was approved, setting a claims bar date of 2024-08-30.
Source: Notice to Claimants
A claims procedure was approved, setting a claims bar date of 2024-08-30.
Source: Revised Claims Procedure Order and Claims Procedure (blackline)
Motion Record of the Receiver was filed. Court file CV-24-00719237-00CL.
Source: Motion Record of the Receiver
Debtor
1001138302 Ontario Inc.
Receiver
FTI
Bench
| Judge | Court | On this docket | Cases on record |
|---|---|---|---|
| Justice Osborne | Ontario Superior Court of Justice | 7 orders, Apr 2024 – Apr 2025 | 146 cases on record |
Counsel of record
| Party | Counsel | First seen | Source |
|---|---|---|---|
| ReceiverFTI | Thornton Grout Finnigan LLP | 28 Jan 2025 | Service list · 28 Jan 2025 |
| Applicant | Bennett Jones LLP | 22 Apr 2024 | Order · 22 Apr 2024 |
| CreditorDavid O'Connor | Roy O'Connor LLP | 28 Jan 2025 | Service list · 28 Jan 2025 |
| CreditorLicensee, Knight Therapeutics | Davies Ward Phillips & Vineberg LLP | 28 Jan 2025 | Service list · 28 Jan 2025 |
| CreditorLotus Clinical Research, LLC | Dla Piper LLP | 28 Jan 2025 | Service list · 28 Jan 2025 |
| CreditorNuance Pharma Ltd | Bennett Jones LLP | 28 Jan 2025 | Service list · 28 Jan 2025 |
| CreditorRoderick Flower, Robert Hoffman, Amal Khouri, Walt MacNee, Jennifer NcNealey and Yung Wu | Lax O'Sullivan Lisus Gottlieb LLP | 28 Jan 2025 | Service list · 28 Jan 2025 |
| CreditorSummit Analytical LLC | Speigel Nichols Fox LLP | 28 Jan 2025 | Service list · 28 Jan 2025 |
| Priority class | Creditor | Amount | Source |
|---|---|---|---|
| Unsecured | Nuance Pharma LimitedLargest creditor; Nuance additionally intends to seek recognition of a constructive trust claim over approx. USD $20 million (original licence-agreement prepayment, subject to a final arbitral award for its return plus interest and costs of approx. USD $4 million) and approx. CAD $19.6 million (cash on hand as of April 8, 2024); if the trust claim succeeds, this would displace some/all of this unsecured amount. Claim disputed/contested by Debtor as to characterization. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $33.8M | Notice and Statement of the Receiver |
| Unsecured | Lotus Clinical Research · in 2 casesOriginal USD amount converted to CAD at FX rate 1.3709 per Schedule C notes. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $3.8M | Notice and Statement of the Receiver |
| Unsecured | Patheon (Thermo Fisher) · in 3 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $1.19M | Notice and Statement of the Receiver |
| Unsecured | Lonza Bend · in 2 casesOriginal USD amount converted to CAD at FX rate 1.3709 per Schedule C notes. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $567K | Notice and Statement of the Receiver |
| Unsecured | ProPharma Group · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $257K | Notice and Statement of the Receiver |
| Unsecured | Ernst & Young · in 11 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $171K | Notice and Statement of the Receiver |
| Unsecured | Paliare Roland · in 2 casesPaliare Roland acted as counsel to Antibe Therapeutics Inc. in the CCAA/receivership proceedings; related-party (professional) claim. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $113K | Notice and Statement of the Receiver |
| Unsecured | Pharma Medica · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $81.7K | Notice and Statement of the Receiver |
| Unsecured | WeirFoulds · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $75.3K | Notice and Statement of the Receiver |
| Unsecured | Lonza Nansha · in 2 casesOriginal CHF/EUR amount converted to CAD per Schedule C notes. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $54.3K | Notice and Statement of the Receiver |
| Unsecured | DWGilroy Consultingdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $52.2K | Notice and Statement of the Receiver |
| Unsecured | Axiom Real-Time Metrics · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $51.5K | Notice and Statement of the Receiver |
| Unsecured | Nucro-Technics · in 3 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $50.9K | Notice and Statement of the Receiver |
| Unsecured | DILIsym Services · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $50.4K | Notice and Statement of the Receiver |
| Unsecured | Bloom Burton Securities Inc. · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $33.9K | Notice and Statement of the Receiver |
| Unsecured | Innomar Strategies · in 3 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $32.7K | Notice and Statement of the Receiver |
| Unsecured | Troutman Pepper · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $32.4K | Notice and Statement of the Receiver |
| Unsecured | Deloitte Restructuring · in 2 casesDeloitte Restructuring Inc. also acted as CCAA Monitor of the Debtor in the prior proceeding; related-party role noted. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $30.1K | Notice and Statement of the Receiver |
| Unsecured | Bereskin & Parr · in 8 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $30.1K | Notice and Statement of the Receiver |
| Unsecured | PharmaWrite · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $29.7K | Notice and Statement of the Receiver |
| Unsecured | Summit Analytical · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $29.4K | Notice and Statement of the Receiver |
| Unsecured | National Institute of Oncology (Budapest) · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $28.8K | Notice and Statement of the Receiver |
| Unsecured | BND Projects · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $21.7K | Notice and Statement of the Receiver |
| Unsecured | Toronto Stock Exchange (TSX) · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $20.8K | Notice and Statement of the Receiver |
| Unsecured | Lonza Tampa · in 2 casesOriginal USD amount converted to CAD at FX rate 1.3709 per Schedule C notes. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $20.7K | Notice and Statement of the Receiver |
| Unsecured | DLA Piper · in 16 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $20.6K | Notice and Statement of the Receiver |
| Unsecured | BCS Statistical Solutions · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $20K | Notice and Statement of the Receiver |
| Unsecured | Norton Rose Fulbright · in 14 casesNorton Rose Fulbright acted as counsel to the CCAA Monitor; potential related-party relationship. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $19.2K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $16.7K | Notice and Statement of the Receiver |
| Unsecured | Klick Health · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $15.3K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $15K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $14.7K | Notice and Statement of the Receiver |
| Unsecured | Uppsala Monitoring Centre · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $14.5K | Notice and Statement of the Receiver |
| Unsecured | FG Pharma · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $13.6K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $12.3K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $12.1K | Notice and Statement of the Receiver |
| Unsecured | CDM Canada Ltd. · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $11.3K | Notice and Statement of the Receiver |
| Unsecured | 14130855 Canada · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $11.3K | Notice and Statement of the Receiver |
| Unsecured | EKS Business Development · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $10.8K | Notice and Statement of the Receiver |
| Unsecured | Charles River CANADA · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $10.4K | Notice and Statement of the Receiver |
| Unsecured | Computershare · in 36 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $9.64K | Notice and Statement of the Receiver |
| Unsecured | Stonehedge Pharma · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $8.12K | Notice and Statement of the Receiver |
| Unsecured | Passageways · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $7.95K | Notice and Statement of the Receiver |
| Unsecured | Elegen Group · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $7.32K | Notice and Statement of the Receiver |
| Unsecured | Business Wire · in 4 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $5.93K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $5.25K | Notice and Statement of the Receiver |
| Unsecured | Fifteen Prince Arthur · in 2 casesLandlord of Debtor's premises at 15 Prince Arthur Avenue. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $5.07K | Notice and Statement of the Receiver |
| Unsecured | Caligor Opco LLC (CalCog) · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $4.8K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $4.7K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $4.31K | Notice and Statement of the Receiver |
| Unsecured | Royal Bank of Canada (Visa) · in 556 casesCredit card facility; classified as unsecured per Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $4.12K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $4.03K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $2.96K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $2.74K | Notice and Statement of the Receiver |
| Unsecured | Scendea · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $2.73K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $2.24K | Notice and Statement of the Receiver |
| Unsecured | Bhito Integrated Solutions · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $1.75K | Notice and Statement of the Receiver |
| Unsecured | R. P. Chiacchierini Consulting · in 2 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $1.68K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $1.4K | Notice and Statement of the Receiver |
| Unsecured | Independent Trading Group · in 8 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $1.36K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $1.1K | Notice and Statement of the Receiver |
| Unsecured | Gowling WLG · in 33 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $1.05K | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $864 | Notice and Statement of the Receiver |
| Unsecured | CDSdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $565 | Notice and Statement of the Receiver |
| Unsecured | CT Corporation · in 8 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $513 | Notice and Statement of the Receiver |
| Unsecured | Individual · in 3 casesIndividual creditor; name not disclosed in Schedule C. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $330 | Notice and Statement of the Receiver |
| Unsecured | Paychexdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $202 | Notice and Statement of the Receiver |
| Unsecured | Bell Canada · in 298 casesdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $86 | Notice and Statement of the Receiver |
| Unsecured | Critical Pathdebtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | $71 | Notice and Statement of the Receiver |
| Unsecured | Minister of Finance - ON · in 2 casesAmount stated as 'TBD' (not yet quantified); provincial governmental/tax authority claim. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | — | Notice and Statement of the Receiver |
| Unsecured | Receiver General (CRA) · in 75 casesAmount stated as 'TBD' (not yet quantified); Canada Revenue Agency claim, deemed trust class. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | — | Notice and Statement of the Receiver |
| Unsecured | IRS Centralized Insolvency OperationAmount stated as 'TBD' (not yet quantified); governmental/tax authority claim. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | — | Notice and Statement of the Receiver |
| Unsecured | Florida Division of Taxation · in 2 casesAmount stated as 'TBD' (not yet quantified); governmental/tax authority claim. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | — | Notice and Statement of the Receiver |
| Unsecured | Hansamed Limited · in 2 casesAmount stated as 'TBD' (not yet quantified). — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | — | Notice and Statement of the Receiver |
| Unsecured | Employees · in 185 casesAmount stated as 'TBD' (not yet quantified). — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | — | Notice and Statement of the Receiver |
| Unsecured | Oklahoma Division of TaxationAmount stated as 'TBD' (not yet quantified); governmental/tax authority claim. — debtor: Antibe Therapeutics Inc. · as of 22 Apr 2024 | — | Notice and Statement of the Receiver |
“not stated” means the record names the claim without a figure; “—” means not in the extracted record.
Sale closed — the Transaction closed and the only remaining realizable assets are certain sales tax refunds of ResidualCoFourth Interim Report of the Receiver- Section 246(2) of the BIA · 7 Jul 2026
| Purchaser | Price | Status | Source |
|---|---|---|---|
| Taro Pharmaceuticals Inc.the Transaction · asset sale · ResidualCo: ResidualCo · agreement 15 Jan 2025 | not statedCash receipts of CAD$4.075 million in relation to the Transaction plus a previously collected deposit of $425 thousand | Closed17 Mar 2025outside 27 Sep 2024 | Fourth Interim Report of the Receiver- Section… |
Unsecured creditors: 42 % of proven claims. Nuance Pharma Ltd. a distribution · Nuance Pharma Ltd. paid in full.FinalFourth Interim Report of the Receiver- Section 246(2) of the BIA · 7 Jul 2026
| Class | Creditor | Claims | Recovery | Basis | Source |
|---|---|---|---|---|---|
| Deemed trust | Nuance Pharma Ltd. | $519K USDproven | a distribution | Finalper the receiver | Second Interim Report of the Receiver- Section 246(2) of the BIA · 30 May 2025 |
| SecuredNuance Distribution | Nuance Pharma Ltd. | — | paid in full | Finalper the receiver | Motion Record · 26 Mar 2025 |
| Preferred | — | — | $2Kinterim | Finalper the receiver | Fourth Interim Report of the Receiver- Section 246(2) of the BIA · 7 Jul 2026 |
| Unsecured | — | — | 42 %of proven claims$17.8Minterim | Finalper the receiver | Fourth Interim Report of the Receiver- Section 246(2) of the BIA · 7 Jul 2026 |
Each row is one filing's statement, copied as it reads and never computed. "Estimated" is the officer's forecast; "Under the plan" is the plan's or proposal's own term; "Final" is a declared or paid distribution; a row with no chip states no footing. A range is the two numbers stated; "of proven claims" is the document's own denominator.
As at 22 Apr 2024 · per per the Information (Receiver's review of Company's books and records, unaudited) · Antibe Therapeutics Inc. - total known unsecured claims only (no secured creditors) — The Receiver states: 'The Receiver is not aware of any secured creditors who currently hold a security interest in the Property of Antibe' (p.9); the Endorsement of Justice Osborne likewise states 'Antibe has no secured creditors' (p.55, original numbering, para 6). Known unsecured claims as at the Date of Appointment (April 22, 2024) totaled approximately $40.9 million, comprised of Nuance's Arbitral Award claim of approximately $33.8 million (~82%) and other unsecured creditors of approximately $7.1 million (~18%). No total assets figure is stated in the excerpted pages.
| Date | Document | File |
|---|---|---|
Fourth Interim Report of the Receiver- Section 246(2) of the BIA
| ||
Third Interim Report of the Receiver- Section 246(2) of the BIA
| ||
Second Interim Report of the Receiver- Section 246(2) of the BIA
| ||
Endorsement
| ||
Interim Distribution Order
| ||
Factum of the Receiver
| ||
First Supplemental Report of the Receiver
| ||
Motion Record
| ||
Receiver's Certificate, re: Closing of sale transaction to Taro Pharmaceuticals Inc.
| ||
Ancillary Order
| ||
Reverse Vesting Order
| ||
Aide Memoire
| ||
Service List
| ||
| Second Report of the Receiver | ||
First Interim Report of the Receiver- Section 246(2) of the BIA
| ||
Fourth Sale Process Letter Update
| ||
Third Sale Process Letter Update
| ||
Second Sale Process Letter Update
| ||
| Proof of Claim Form for Claims against Antibe Therapeutics Inc. | ||
| Proof of Claim Instruction Letter | ||
Sale Process Letter Update
| ||
Notice to Claimants
| ||
Claims Procedure Order
| ||
Revised Claims Procedure Order and Claims Procedure
| ||
Revised Claims Procedure Order and Claims Procedure (blackline)
| ||
Sale Process Order
| ||
Motion Record of the Receiver
| ||
First Report of the Receiver
| ||
Notice and Statement of the Receiver
| ||
Order (appointing Receiver) of Justice Osborne
| ||
| Notice of Dispute of Revision or Disallowance | ||
Filing titles, dates, and extracted key facts are public.
CiteProceedings., “1001138302 Ontario Inc.” (Receivership (court-appointed)), Ontario Superior Court of Justice · Commercial List. Retrieved 20 September 2026, https://proceedings.ca/case/1001138302-ontario-inc
Sources last checked · summary updated 8 August 2026 · Report a correction · Printed from proceedings.ca/case/1001138302-ontario-inc
Facts and summaries are extracted automatically from the court filings linked on each page; the filings remain the authoritative record. Suggested corrections are reviewed against the source filings.